carnitine has been researched along with Seizures in 41 studies
Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Warnings of L-carnitine induced seizures are recorded on product monographs and pharmacy databases, without any referenced literature." | 8.93 | Levocarnitine induced seizures in patients on valproic acid: A negative systematic review. ( Gillman, LM; Sader, N; West, M; Zeiler, FA, 2016) |
| "When ddY mice were pretreated with L-carnitine (5, 10 or 20 mmol/kg), clonic as well as tonic seizures induced by pentylenetetrazol (PTZ) were dose-dependently suppressed." | 7.69 | Suppression of pentylenetetrazol-induced seizures by carnitine in mice. ( Igisu, H; Ikeda, M; Iryo, Y; Matsuoka, M; Yu, Z, 1997) |
| "Acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) is the most prevalent encephalopathy in Japanese children." | 5.51 | Early administration of vitamins B1 and B6 and l-carnitine prevents a second attack of acute encephalopathy with biphasic seizures and late reduced diffusion: A case control study. ( Fukui, KO; Ishiguro, A; Kashii, H; Kubota, M; Terashima, H, 2019) |
| "No further seizures were noted by day 5." | 5.51 | A newborn with seizures born to a mother diagnosed with primary carnitine deficiency. ( Chen, S; Hu, Y; Huang, Y; Lin, J; Lin, Z; Nan, Y; Zhou, X, 2019) |
| "Valproic acid is a broad-spectrum anticonvulsant that has also gained attention in the psychiatric setting." | 5.46 | L-Carnitine supplementation to reverse hyperammonemia in a patient undergoing chronic valproic acid treatment: A case report. ( Fagiolino, P; Guevara, N; Maldonado, C; Silveira, A; Vázquez, M, 2017) |
| "Carnitine levels in CSF were 1/10 compared with serum in normal febrile children." | 5.30 | CSF levels of carnitine in children with meningitis, neurologic disorders, acute gastroenteritis, and seizure. ( Gruener, N; Lerner, A; Shinawi, M, 1998) |
| "Warnings of L-carnitine induced seizures are recorded on product monographs and pharmacy databases, without any referenced literature." | 4.93 | Levocarnitine induced seizures in patients on valproic acid: A negative systematic review. ( Gillman, LM; Sader, N; West, M; Zeiler, FA, 2016) |
| "Valproic acid is approved for treatment of seizures and manic episodes of bipolar disorder, and continues to be one of the most commonly prescribed antiepileptic drugs in the world." | 4.90 | Evidence for a potential protective effect of carnitine-pantothenic acid co-treatment on valproic acid-induced hepatotoxicity. ( Felker, D; Johnson, DE; Lynn, A; Wang, S, 2014) |
| "We report the case of an aborted awake craniotomy for a left frontotemporoinsular glioma due to ammonia encephalopathy on a patient taking Levetiracetam, valproic acid and clobazam." | 3.81 | Ammonia encephalopathy and awake craniotomy for brain language mapping: cause of failed awake craniotomy. ( Arroyo Pérez, R; Fernández-Candil, JL; León Jorba, A; Pacreu Terradas, S; Villalba Martínez, G; Vivanco-Hidalgo, RM, 2015) |
| "This prospective study was designed to investigate whether or not monotherapy with sodium valproate (VPA) or oxcarbazepine (OXC) affects plasma levels of fatty acylcarnitine esters in children with epilepsy." | 3.77 | Analysis of acylcarnitine levels by tandem mass spectrometry in epileptic children receiving valproate and oxcarbazepine. ( Biberoglu, G; Cansu, A; Ezgu, FS; Hasanoglu, A; Hirfanoglu, TL; Serdaroglu, A; Tumer, L, 2011) |
| " Laboratory data showed hypoglycemia and hypocarnitinemia." | 3.74 | Carnitine-associated encephalopathy caused by long-term treatment with an antibiotic containing pivalic acid. ( Ito, T; Koyama, N; Makino, Y; Sugiura, T; Sugiyama, N, 2007) |
| " Laboratory evaluation revealed hypoglycemia, hyperammonemia, lactic acidemia, hyperuricemia, and mild dicarboxylic aciduria." | 3.70 | Carnitine-acylcarnitine translocase deficiency: metabolic consequences of an impaired mitochondrial carnitine cycle. ( Dorland, L; Duran, M; IJlst, L; Muntau, AC; Roscher, AA; Röschinger, W; Wanders, RJ, 2000) |
| " Serum L-carnitine levels normalized after correction; sequelae included seizures in two patients, hemiparesis in one patient, normal outcome in one patient, and death in one patient." | 3.69 | MR in children with L-carnitine deficiency. ( Barrow, M; Castillo, M; Mukherji, SK; Smith, M; Thompson, JE, 1996) |
| "When ddY mice were pretreated with L-carnitine (5, 10 or 20 mmol/kg), clonic as well as tonic seizures induced by pentylenetetrazol (PTZ) were dose-dependently suppressed." | 3.69 | Suppression of pentylenetetrazol-induced seizures by carnitine in mice. ( Igisu, H; Ikeda, M; Iryo, Y; Matsuoka, M; Yu, Z, 1997) |
| " Administration of ammonium acetate (15 mmol/kg) to mice caused seizures, elevation of blood ammonia and urea concentrations, and marked alterations of brain energy metabolites." | 3.68 | Comparison of the effects of L-carnitine, D-carnitine and acetyl-L-carnitine on the neurotoxicity of ammonia. ( Igisu, H; Matsuoka, M, 1993) |
| "Acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) is the most prevalent encephalopathy in Japanese children." | 1.51 | Early administration of vitamins B1 and B6 and l-carnitine prevents a second attack of acute encephalopathy with biphasic seizures and late reduced diffusion: A case control study. ( Fukui, KO; Ishiguro, A; Kashii, H; Kubota, M; Terashima, H, 2019) |
| "No further seizures were noted by day 5." | 1.51 | A newborn with seizures born to a mother diagnosed with primary carnitine deficiency. ( Chen, S; Hu, Y; Huang, Y; Lin, J; Lin, Z; Nan, Y; Zhou, X, 2019) |
| "Valproic acid is a broad-spectrum anticonvulsant that has also gained attention in the psychiatric setting." | 1.46 | L-Carnitine supplementation to reverse hyperammonemia in a patient undergoing chronic valproic acid treatment: A case report. ( Fagiolino, P; Guevara, N; Maldonado, C; Silveira, A; Vázquez, M, 2017) |
| "Patient with symptomatic generalized epilepsy may be particularly good candidates for this type of dietary treatment." | 1.40 | Ketogenic diet in adolescents and adults with epilepsy. ( Nei, M; Ngo, L; Sirven, JI; Sperling, MR, 2014) |
| "At 6 weeks of age she started with convulsions reaching up to 20 myoclonic seizures a day." | 1.34 | [Glucose transponer type 1 deficiency síndrome (GLUT-1 SD) treated with ketogenic diet. Report of one case]. ( Cabello, JF; Colombo, MC; Cornejo, VE; Raimann, EB, 2007) |
| "Her symptoms consisted of a few convulsions between 2." | 1.33 | [Glutaric aciduria type 1 with normal evolution: follow-up of one case until adult age]. ( Garcia-Segura, JM; Merinero, B; Pascual-Castroviejo, I; Pascual-Pascual, SI; Ugarte, M; Velazquez, R; Viaño, J, 2005) |
| "Predominant clinical features include microcephaly, hydrocephalus, seizures, and white-matter changes on magnetic resonance imaging in early-onset cases." | 1.31 | Practical management of combined methylmalonicaciduria and homocystinuria. ( Bodamer, OA; Smith, DL, 2002) |
| "A boy had neonatal seizure, lethargy, and metabolic acidosis at presentation." | 1.30 | Very long chain acyl-coenzyme A dehydrogenase deficiency in two siblings: evolution after prenatal diagnosis and prompt management. ( Brivet, M; Hubinont, C; Sluysmans, T; Tuerlinckx, D; Verellen-Dumoulin, C; Vianey-Saban, C, 1997) |
| "Carnitine levels in CSF were 1/10 compared with serum in normal febrile children." | 1.30 | CSF levels of carnitine in children with meningitis, neurologic disorders, acute gastroenteritis, and seizure. ( Gruener, N; Lerner, A; Shinawi, M, 1998) |
| "Both convulsions and mortality percentages are more significantly reduced in treated animals with these two substances in combination rather than separately." | 1.28 | Protective synergic effect of coenzyme Q10 and carnitine on hyperbaric oxygen toxicity. ( Bertelli, A; Bertelli, AA; Giovannini, L; Spaggiari, P, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (19.51) | 18.7374 |
| 1990's | 14 (34.15) | 18.2507 |
| 2000's | 9 (21.95) | 29.6817 |
| 2010's | 10 (24.39) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maldonado, C | 1 |
| Guevara, N | 1 |
| Silveira, A | 1 |
| Fagiolino, P | 1 |
| Vázquez, M | 1 |
| Fukui, KO | 1 |
| Kubota, M | 1 |
| Terashima, H | 1 |
| Ishiguro, A | 1 |
| Kashii, H | 1 |
| Chen, S | 2 |
| Hu, Y | 1 |
| Huang, Y | 1 |
| Nan, Y | 1 |
| Zhou, X | 1 |
| Lin, J | 1 |
| Lin, Z | 1 |
| Felker, D | 1 |
| Lynn, A | 1 |
| Wang, S | 1 |
| Johnson, DE | 1 |
| Nei, M | 1 |
| Ngo, L | 1 |
| Sirven, JI | 1 |
| Sperling, MR | 1 |
| Villalba Martínez, G | 1 |
| Fernández-Candil, JL | 1 |
| Vivanco-Hidalgo, RM | 1 |
| Pacreu Terradas, S | 1 |
| León Jorba, A | 1 |
| Arroyo Pérez, R | 1 |
| Zeiler, FA | 1 |
| Sader, N | 1 |
| Gillman, LM | 1 |
| West, M | 1 |
| Zelnik, N | 1 |
| Isler, N | 1 |
| Goez, H | 1 |
| Shiffer, M | 1 |
| David, M | 1 |
| Shahar, E | 1 |
| Napolitano, C | 1 |
| Scaglianti, M | 1 |
| Scalambra, E | 1 |
| Manfredini, S | 1 |
| Ferraro, L | 1 |
| Beggiato, S | 1 |
| Vertuani, S | 1 |
| Das, S | 1 |
| Joardar, S | 1 |
| Chatterjee, R | 1 |
| Guha, G | 1 |
| Hashmi, MA | 1 |
| Cansu, A | 1 |
| Serdaroglu, A | 1 |
| Biberoglu, G | 1 |
| Tumer, L | 1 |
| Hirfanoglu, TL | 1 |
| Ezgu, FS | 1 |
| Hasanoglu, A | 1 |
| Listernick, R | 1 |
| Smith, DL | 1 |
| Bodamer, OA | 1 |
| HOSEIN, EA | 2 |
| Pascual-Castroviejo, I | 1 |
| Pascual-Pascual, SI | 1 |
| Merinero, B | 1 |
| Ugarte, M | 1 |
| Garcia-Segura, JM | 1 |
| Viaño, J | 1 |
| Velazquez, R | 1 |
| Cornejo, VE | 1 |
| Cabello, JF | 1 |
| Colombo, MC | 1 |
| Raimann, EB | 1 |
| Makino, Y | 1 |
| Sugiura, T | 1 |
| Ito, T | 1 |
| Sugiyama, N | 1 |
| Koyama, N | 1 |
| Maegawa, GH | 1 |
| Poplawski, NK | 1 |
| Andresen, BS | 1 |
| Olpin, SE | 1 |
| Nie, G | 1 |
| Clarke, JT | 1 |
| Teshima, I | 1 |
| Gozsy, B | 1 |
| Kato, L | 1 |
| Roy, PB | 1 |
| Kato, G | 1 |
| Bernardi, M | 1 |
| Bertolini, A | 1 |
| Ferrari, F | 1 |
| Greggia, A | 1 |
| Corbett, R | 1 |
| Leonard, BE | 1 |
| Ater, SB | 1 |
| Swinyard, EA | 1 |
| Tolman, KG | 1 |
| Madsen, JA | 1 |
| Matsuo, F | 1 |
| Fariello, RG | 1 |
| Zeeman, E | 1 |
| Golden, GT | 1 |
| Reyes, PT | 1 |
| Ramacci, T | 1 |
| Igisu, H | 4 |
| Matsuoka, M | 4 |
| Iryo, Y | 2 |
| Van Wouwe, JP | 1 |
| Thompson, JE | 1 |
| Smith, M | 1 |
| Castillo, M | 1 |
| Barrow, M | 1 |
| Mukherji, SK | 1 |
| Herink, J | 1 |
| Yu, Z | 1 |
| Ikeda, M | 1 |
| Sluysmans, T | 1 |
| Tuerlinckx, D | 1 |
| Hubinont, C | 1 |
| Verellen-Dumoulin, C | 1 |
| Brivet, M | 1 |
| Vianey-Saban, C | 1 |
| Shinawi, M | 1 |
| Gruener, N | 1 |
| Lerner, A | 1 |
| Steen, C | 1 |
| Baumgartner, ER | 1 |
| Duran, M | 2 |
| Lehnert, W | 1 |
| Suormala, T | 1 |
| Fingerhut, R | 1 |
| Stehn, M | 1 |
| Kohlschütter, A | 1 |
| Röschinger, W | 1 |
| Muntau, AC | 1 |
| Dorland, L | 1 |
| IJlst, L | 1 |
| Wanders, RJ | 1 |
| Roscher, AA | 1 |
| Sanford, MG | 1 |
| Ryan, C | 1 |
| Cummings, AD | 1 |
| Hunt, A | 1 |
| Hackes, B | 1 |
| Murakami, K | 1 |
| Sugimoto, T | 1 |
| Nishida, N | 1 |
| Kobayashi, Y | 1 |
| Kuhara, T | 1 |
| Matsumoto, I | 1 |
| Kohriyama, K | 1 |
| Inoue, N | 1 |
| Hug, G | 1 |
| McGraw, CA | 1 |
| Bates, SR | 1 |
| Landrigan, EA | 1 |
| Bertelli, A | 2 |
| Giovannini, L | 2 |
| Mian, M | 1 |
| Spaggiari, PG | 1 |
| Bertelli, AA | 1 |
| Spaggiari, P | 1 |
| Rodriguez-Segade, S | 1 |
| de la Peña, CA | 1 |
| Tutor, JC | 1 |
| Paz, JM | 1 |
| Fernandez, MP | 1 |
| Rozas, I | 1 |
| Del Río, R | 1 |
| Millington, DS | 1 |
| Bohan, TP | 1 |
| Roe, CR | 1 |
| Yergey, AL | 1 |
| Liberato, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy[NCT00374075] | Phase 1 | 42 participants | Interventional | 2003-09-30 | Completed | ||
| Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)[NCT00661453] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Multi-center Phase II Trial of Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy (SMA CARNI-VAL Trial)[NCT00227266] | Phase 2 | 94 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00661453)
Timeframe: -2 weeks, time 0, 3 months, 6 months
| Intervention | g (Mean) | |||||
|---|---|---|---|---|---|---|
| Lean Mass Baseline | Lean Mass 3 months | Lean Mass 6 months | Fat Mass Baseline | Fat Mass 3 months | Fat Mass 6 months | |
| SMA Type 1 | 4317.15 | 4993.92 | 5133.83 | 3011.37 | 3618.25 | 4316.08 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 2.28 | 2.32 |
| Cohort 1b Sitters Treatment | 2.93 | 2.37 |
| Cohort 2 Standers and Walkers - Treatment | 5.52 | 6.56 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 1.91 | 1.44 |
| Cohort 1b Sitters Treatment | 2.2 | 1.8 |
| Cohort 2 Standers and Walkers - Treatment | 5.3 | 5.85 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 5.46 | 5.28 |
| Cohort 1b Sitters Treatment | 5.45 | 5.26 |
| Cohort 2 Standers and Walkers - Treatment | 14.85 | 16.26 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 3.6 | 3.74 |
| Cohort 1b Sitters Treatment | 4.6 | 3.4 |
| Cohort 2 Standers and Walkers - Treatment | 13.65 | 16.85 |
Comparison of Modified Hammersmith Change from baseline to 6 months. Scores range from 0 to 40. A higher score indicates a better outcome. This scale is used to assess gross motor abilities of non-ambulant children with SMA in multiple research trials as well as in clinical settings. (NCT00227266)
Timeframe: 0 months, 6 months
| Intervention | Score (Mean) | ||
|---|---|---|---|
| Baseline visit (0 weeks) | 6 Month visit (V2) | Change from Baseline | |
| Cohort 1a Sitters Placebo Then Treatment | 20.0 | 20.6 | 0.6 |
| Cohort 1b Sitters Treatment | 16.6 | 16.8 | 0.2 |
"Baseline Modified Hammersmith Extend testing. The baseline test is the score they receive during their screening visits. This scale ranges from 0 to 56. A higher score indicates a better outcome.~This scale is used to assess gross motor abilities of children with SMA in multiple research trials as well as in clinical settings." (NCT00227266)
Timeframe: 1 month prior to enrollment, at enrollment (0 months)
| Intervention | Score (Mean) | |
|---|---|---|
| Modified Hammersmith Extend at S1 (-4 weeks) | Modified Hammersmith Extend at S2 (0 weeks) | |
| Cohort 2 Experimental | 47.0 | 48.3 |
4 reviews available for carnitine and Seizures
| Article | Year |
|---|---|
Evidence for a potential protective effect of carnitine-pantothenic acid co-treatment on valproic acid-induced hepatotoxicity.
Topics: Animals; Anticonvulsants; Bipolar Disorder; Carnitine; Chemical and Drug Induced Liver Injury; Child | 2014 |
Levocarnitine induced seizures in patients on valproic acid: A negative systematic review.
Topics: Anticonvulsants; Carnitine; Databases, Factual; Humans; Seizures; Valproic Acid | 2016 |
Interstitial deletion of 1p22.2p31.1 and medium-chain acyl-CoA dehydrogenase deficiency in a patient with global developmental delay.
Topics: Acyl-CoA Dehydrogenase; Carnitine; Child; Chromosome Deletion; Chromosomes, Human, Pair 1; Dicarboxy | 2008 |
Protection of the brain by carnitine.
Topics: Ammonia; Animals; Brain; Brain Ischemia; Carnitine; Energy Metabolism; Humans; Mice; Seizures; Tauri | 1995 |
37 other studies available for carnitine and Seizures
| Article | Year |
|---|---|
L-Carnitine supplementation to reverse hyperammonemia in a patient undergoing chronic valproic acid treatment: A case report.
Topics: Adult; Anticonvulsants; Carnitine; Female; Humans; Hyperammonemia; Seizures; Valproic Acid | 2017 |
Early administration of vitamins B1 and B6 and l-carnitine prevents a second attack of acute encephalopathy with biphasic seizures and late reduced diffusion: A case control study.
Topics: Brain Diseases; Carnitine; Case-Control Studies; Child, Preschool; Diagnosis, Differential; Disease | 2019 |
A newborn with seizures born to a mother diagnosed with primary carnitine deficiency.
Topics: Brain; Cardiomyopathies; Carnitine; Electroencephalography; Female; Fetal Diseases; Humans; Hyperamm | 2019 |
Ketogenic diet in adolescents and adults with epilepsy.
Topics: Adolescent; Adult; Carnitine; Child; Cholesterol; Diet, Ketogenic; Electrocardiography; Epilepsies, | 2014 |
Ammonia encephalopathy and awake craniotomy for brain language mapping: cause of failed awake craniotomy.
Topics: Anesthesia, General; Anesthesia, Local; Anticonvulsants; Aphasia; Benzodiazepines; Brain Diseases; B | 2015 |
Vigabatrin, lamotrigine, topiramate and serum carnitine levels.
Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Female; Fructose; Humans; Infant; L | 2008 |
Carnitine conjugate of nipecotic acid: a new example of dual prodrug.
Topics: Animals; Brain; Carnitine; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Mice; Nipe | 2009 |
Rare magnetic resonance imaging findings in medium-chain acyl-coenzyme A dehydrogenase deficiency.
Topics: Acyl-CoA Dehydrogenase; Anticonvulsants; Basal Ganglia; Brain; Brain Ischemia; Carnitine; Cerebral I | 2011 |
Analysis of acylcarnitine levels by tandem mass spectrometry in epileptic children receiving valproate and oxcarbazepine.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Carnitine; Child; Child, Preschool; Chromatography, High | 2011 |
A 14-year-old boy with vomiting.
Topics: Abdominal Pain; Adolescent; Brain Ischemia; Carnitine; Cognition Disorders; Diagnosis, Differential; | 2012 |
Practical management of combined methylmalonicaciduria and homocystinuria.
Topics: Adolescent; Adult; Betaine; Carnitine; Child; Child, Preschool; Female; Folic Acid; Gastrointestinal | 2002 |
The isolation of gamma-butyrobetaine, crotonbetaine and carnitine from brains of animals killed during induced convulsions.
Topics: Alkaloids; Animals; Betaine; Brain; Carnitine; Folic Acid; Seizures; Vitamin B Complex | 1963 |
[Glutaric aciduria type 1 with normal evolution: follow-up of one case until adult age].
Topics: Basal Ganglia; Brain; Brain Chemistry; Brain Diseases, Metabolic, Inborn; Carnitine; Cells, Cultured | 2005 |
[Glucose transponer type 1 deficiency síndrome (GLUT-1 SD) treated with ketogenic diet. Report of one case].
Topics: Anticonvulsants; Blood Glucose; Carbohydrate Metabolism, Inborn Errors; Carnitine; Dietary Fats; Ery | 2007 |
Carnitine-associated encephalopathy caused by long-term treatment with an antibiotic containing pivalic acid.
Topics: Acidosis; Anti-Bacterial Agents; Brain Diseases, Metabolic; Carnitine; Cephalosporins; Humans; Hypog | 2007 |
Effect of prolonged treatment with electroshock, metrazol, carnitine and anectine on the capillary permeability.
Topics: Animals; Capillary Permeability; Carnitine; Electric Stimulation; Electroshock; Female; Histamine; M | 1967 |
[Activation of the acetylation in vivo of sulfamide by DL-acetylcarnitine].
Topics: Acetates; Animals; Carbon Tetrachloride Poisoning; Carnitine; Chemical and Drug Induced Liver Injury | 1967 |
Effects of carnitine on changes caused by chronic administration of alcohol.
Topics: Alcoholism; Animals; Ca(2+) Mg(2+)-ATPase; Calcium-Transporting ATPases; Carnitine; Exploratory Beha | 1984 |
Effects of SKF525A, phenobarbital, fasting, and carnitine on the anticonvulsant activity and neurotoxicity of valproate in mice.
Topics: Animals; Carnitine; Fasting; Male; Mice; Mice, Inbred Strains; Nervous System; Phenobarbital; Proadi | 1984 |
Transient seizure activity induced by acetylcarnitine.
Topics: Acetylcarnitine; Animals; Atropine; Carnitine; Cerebral Cortex; Electroencephalography; gamma-Aminob | 1984 |
Comparison of the effects of L-carnitine, D-carnitine and acetyl-L-carnitine on the neurotoxicity of ammonia.
Topics: Acetates; Acetylcarnitine; Ammonia; Animals; Brain; Carnitine; Male; Mice; Neurotoxins; Seizures; St | 1993 |
Carnitine deficiency during valproic acid treatment.
Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma | 1995 |
Carnitine deficiency during valproic acid treatment.
Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma | 1995 |
Carnitine deficiency during valproic acid treatment.
Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma | 1995 |
Carnitine deficiency during valproic acid treatment.
Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma | 1995 |
Carnitine deficiency during valproic acid treatment.
Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma | 1995 |
Carnitine deficiency during valproic acid treatment.
Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma | 1995 |
Carnitine deficiency during valproic acid treatment.
Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma | 1995 |
Carnitine deficiency during valproic acid treatment.
Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma | 1995 |
Carnitine deficiency during valproic acid treatment.
Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma | 1995 |
MR in children with L-carnitine deficiency.
Topics: Adolescent; Carnitine; Cause of Death; Cerebral Hemorrhage; Cerebral Infarction; Cerebral Ventricles | 1996 |
Enhancing effect of L-carnitine on some abnormal signs induced by pentylenetetrazol.
Topics: Animals; Blood-Brain Barrier; Carnitine; Convulsants; Male; Pentylenetetrazole; Rats; Rats, Wistar; | 1996 |
Suppression of pentylenetetrazol-induced seizures by carnitine in mice.
Topics: Animals; Brain; Carnitine; Dose-Response Relationship, Drug; Energy Metabolism; Male; Mice; Pentylen | 1997 |
Very long chain acyl-coenzyme A dehydrogenase deficiency in two siblings: evolution after prenatal diagnosis and prompt management.
Topics: Acidosis; Acyl-CoA Dehydrogenase, Long-Chain; Amniocentesis; Carnitine; Diagnosis, Differential; Fat | 1997 |
CSF levels of carnitine in children with meningitis, neurologic disorders, acute gastroenteritis, and seizure.
Topics: Adolescent; Carnitine; Child; Child, Preschool; Female; Fever; Gastroenteritis; Humans; Infant; Infa | 1998 |
Metabolic stroke in isolated 3-methylcrotonyl-CoA carboxylase deficiency.
Topics: Amino Acid Metabolism, Inborn Errors; Carbon-Carbon Ligases; Carnitine; Diet, Protein-Restricted; Fa | 1999 |
Carnitine-acylcarnitine translocase deficiency: metabolic consequences of an impaired mitochondrial carnitine cycle.
Topics: Ammonia; Cardiac Output, Low; Carnitine; Carnitine Acyltransferases; Cells, Cultured; Coma; Consangu | 2000 |
Protocols for identifying drug-nutrient interactions in patients: the role of the dietitian.
Topics: Adolescent; Adult; Anticonvulsants; Biotin; Calcium; Carnitine; Dietetics; Edema; Folic Acid; Food-D | 2002 |
Abnormal metabolism of carnitine and valproate in a case of acute encephalopathy during chronic valproate therapy.
Topics: Brain Diseases; Carnitine; Cerebral Palsy; Child; Chronic Disease; Female; Gas Chromatography-Mass S | 1992 |
Suppression of neurotoxicity of ammonia by L-carnitine.
Topics: Ammonia; Animals; Behavior, Animal; Brain Chemistry; Carnitine; Energy Metabolism; Male; Mice; Mice, | 1991 |
Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in children.
Topics: Analysis of Variance; Carbamazepine; Carnitine; Child; Drug Combinations; Fatty Acids; Fatty Acids, | 1991 |
Protective action of propionyl-L-carnitine on toxicity induced by hyperbaric oxygen.
Topics: Animals; Carnitine; Hyperbaric Oxygenation; Lung Diseases; Male; Mice; Seizures | 1990 |
Protective synergic effect of coenzyme Q10 and carnitine on hyperbaric oxygen toxicity.
Topics: Animals; Carnitine; Coenzymes; Drug Synergism; Drug Therapy, Combination; Hyperbaric Oxygenation; Ma | 1990 |
Carnitine deficiency associated with anticonvulsant therapy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Carnitine; Cerebral Palsy; Drug Therapy, Co | 1989 |
Valproylcarnitine: a novel drug metabolite identified by fast atom bombardment and thermospray liquid chromatography-mass spectrometry.
Topics: Adolescent; Carnitine; Child; Child, Preschool; Chromatography, High Pressure Liquid; Humans; Isomer | 1985 |